Back to search
Advanced HR+/HER2- Breast Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced HR+/HER2- Breast Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced HR+/HER2- Breast Cancer trials you may qualify forThe purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- br…
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-can…
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 + fulvestrant to capivasertib + fulvestrant fo…
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- br…
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatmen…
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectab…
Phase I: Characterize safety and tolerability of ERW316 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization…